Clinical trial · Interventional
Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy
NCT05822518CI-TRIAL-00075394completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the outcome of perioperative immune-nutrition with glutamine, arginine and fish oil in patients undergoing radical cystectomy as regards to enhancement of healing, increasing immunity and improving overall health status.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Bladder | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Cystostomy; Complications | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dipeptiven solution (Fresenius Kabi pharmaceutical) | Drug | — | UNRESOLVED |
| Neo-mune powder (otsuka pharmaceutical) | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- conventional protocol group
- description
- patients who are enrolled in conventional pre and post operative routine preparation for surgery protocol.
- type
- ACTIVE_COMPARATOR
- label
- immune enhancing nutrition protocol group
- description
- patients who are enrolled in pre and post operative routine preparation for surgery protocol plus immune enhancing nutrition administration pre and post operatively.
- interventionNames
- Dietary Supplement: Neo-mune powder (otsuka pharmaceutical)
- Drug: Dipeptiven solution (Fresenius Kabi pharmaceutical)
Primary outcomes (3)
- measure
- Postoperative complications
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with CT showing bladder mass with radiological staging of T2 or T3. 2. Patients pathologically proven to have cancer bladder. 3. Patients undergoing radical cystectomy with ileal conduit. 4. The American Society of Anesthesiologists Physical Status classification system (ASA PS) of 1, 2 or 3. Exclusion Criteria: 1. Coagulopathy. 2. Distant metastasis. 3. Body mass index less than 18.5. 4. Relevant food allergies. 5. Severe renal and hepatic insufficiency.
References
Publications (0)
Data not yet available
No reference posted for this study.